Attachment A **(Marked-up Claims)**

7. (First Amended) A method for expressing an increased number of B7 molecules on the surface of an antigen presenting cell to [more efficiently potentiate] enhance or regulate [the] an immune system comprising the steps of:

obtaining an upregulating agent;

administering the upregulating agent to an organism; and,

allowing an upregulation of B7 molecules on a cell whereby an expression of the B7 molecules allows reaction with an effector cell, the reaction with the armed effector cell potentiating an immune response.[.]

8. The method of Claim 7 wherein the upregulating agent is a glucan-containing composition.

9. The method of Claim 7 wherein the cells are antigen presenting cells selected from the group comprising macrophages, B lymphocytes, and dendritic cells.

10. The method of Claim 7 wherein the effector cell is a lymphocyte.

11. The method of Claim 10 wherein the lymphocyte is a T-Lymphocyte.

12. The method of Claim 7 wherein the B7 molecule is selected from the group comprising B7.1 [, B7,2 and B7.3], B7.2, B7h, B7-H1, B7-DC, and B7-H3.

13. The method of Claim 7 wherein the upregulating agent is administered as a pharmacological agent.

14. The method of Claim 13 wherein the pharmacological agent is a tablet.

15. The method of Claim 13 wherein the pharmacological agent is a capsule.

16. The method of Claim 13 wherein the pharmacological agent is a powder.

17. The method of Claim 13 wherein the pharmacological agent is a liquid.

22. The method of Claim 7, wherein the glucan containing composition at least comprises β 1,3-glucans.

23. The method of Claim 22, wherein the glucan containing composition further comprises β 1,6-glucans.

24. The method of Claim 7, wherein the glucan-containing composition is primarily comprised of microparticulate β glucan.